Sebia reagents and services

The Florida Department of Health, Bureau of Public Health Laboratories (BPHL) Newborn Screening Unit is soliciting a single source purchase for reagents, controls, calibrators, consumables, and services for the FDA-approved CAPILLARS 3 DBS automated analyzer. This procurement is issued by the state of Florida under the jurisdiction of Leon County and is intended to support qualitative screening for the detection of normal and abnormal hemoglobin in newborn dry blood samples. The primary objectives are to enable simultaneous testing of multiple parameters, improve accuracy in early screening of genetic and inheritable disorders in newborns, and ensure reliable results necessary for immediate clinical intervention. The contract term is three years. The deadline for receipt of information is June 3, 2026, at 1:30 PM. The requestor is Yasemin Sulker, Bureau of Public Health Laboratories, who can be contacted at 850-245-4931 or Yasemin.Sulker@flhealth.gov. The internal tracking number for this procurement is EXP2670.

This single source procurement is restricted to Sebia, Inc., the sole manufacturer and distributor of the CAPILLARS 3 DBS automated analyzer and all associated proprietary reagents, controls, calibrators, and consumables. The justification for single source acquisition is based on Sebia's exclusive FDA approval for this specific analyzer system and the proprietary nature of the components, which ensures standardized, reliable, and scientifically validated diagnostic results. No set-aside designations or restrictions for disadvantaged enterprises are noted in the procurement documents. The estimated award value for this three-year contract is $2,695,571.00. The purchase was approved by Sonja German, Purchasing Director. This procurement is issued in accordance with Chapter 60A-1.045, F.A.C., which authorizes single source purchases under specified circumstances.